Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy (TripleEX)

Malcolm Kohler

Status: Completed

Conditions: COPD Exacerbation

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04638920

BASEC-Nr. 2020-01954

Details and patient eligibility

About

Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation. Furthermore, breath patterns will be assessed for correlation and association with clinical outcomes and treatment.

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent
• age >= 18 years
• staged according to GOLD recommendations
• GOLD stage 2-4, GOLD ABE classification
• hospitalization due to COPD exacerbation
• subjects adherent to triple inhalational therapy (beta-2-sympathomimetics, anticholinergics, steroids)
• suitable for follow-up assessment
• <48 hours after initiation of antibiotic therapy or systemic steroid therapy

Exclusion criteria

• physical or intellectual impairment precluding informed consent or protocol adherence
• known pregnancy
• congenital defects with direct impact on central metabolism e.g. amino acid metabolism defect
• uncontrolled diabetes (e.g. HbA1c >11% or Glc >20mmol/l)
• acute or chronic pulmonary disease other than COPD
• renal failure or renal replacement therapy (GFR < 15 mL/min)

Trial design

35 participants in 1 patient group

Exacerbators

Description:

Patients with acute COPD exacerbation under triple inhalation therapy

Treatment:

Other: No intervention